Michigan’s adult-use cannabis market generated sales totaling US$258.17 million in April, according to data from the state’s Cannabis Regulatory Agency. This figure indicates a market rebound following earlier performance metrics, with specific days contributing significantly to the monthly total. The sustained activity in Michigan’s regulated sector provides ongoing data for market analysis and regulatory oversight.
April Sales Performance and Market Rebound
The April sales performance was notably bolstered by a single-day total of US$20.4 million on April 20, as reported by the Michigan Cannabis Industry Association. This daily figure represents an increase compared to the approximately US$16 million recorded on April 20 of the previous year. The prior year’s sales on that date were potentially affected by its coincidence with Easter Sunday, which may have influenced consumer purchasing patterns.
The US$258.17 million in Michigan adult-use cannabis sales for April marks an increase from the US$224.4 million reported in January. The January figure represented the lowest monthly sales total since February 2023, indicating a recovery trend within the market. These statistics were outlined by Ganjapreneur, citing data from WZZM13.
Wholesale Tax and Evolving Market Dynamics
The Michigan adult-use cannabis market is currently operating under a 24% wholesale tax, which state lawmakers implemented last year. This tax is a significant factor in the financial structure of the industry. Robin Schneider, executive director of the Michigan Cannabis Industry Association, commented to WZZM13 that while the industry is experiencing the effects of this tax, the full impact on consumer retail prices may not yet be evident. Schneider stated, “We’re not to the point where customers are seeing that wholesale tax yet. [The retailers] still largely selling through the product that they purchased prior to the wholesale tax.” This suggests a lag between wholesale cost increases and retail price adjustments.
Prior to the full rollout of the wholesale tax, the year 2025 saw retailers establish a new record for per-pound sales. Despite this increase in volume, overall sales totals for 2025 decreased for the first time since the Michigan market’s launch. This reduction in total revenue was primarily attributed to lower average prices. In 2025, retailers sold 260,000 more pounds of cannabis compared to 2024, yet total sales amounted to approximately US$3.17 billion, which was US$113 million less than the 2024 sales total. This trend highlights a market where increased supply and competitive pricing have influenced revenue despite higher volumes.
Pricing Trends and Industry Outlook
Analysis of the April sales data indicates that the average price of an ounce of adult-use cannabis flower was US$59.05. This figure reflects a slight increase from the US$58.22 per ounce recorded at the close of 2025. Such pricing fluctuations are critical indicators for businesses operating within the sector, influencing inventory management, revenue projections, and competitive positioning. The stability or volatility of per-ounce pricing can affect profitability margins for cultivators, processors, and retailers alike.
The ongoing performance of Michigan’s adult-use cannabis market remains a subject of close observation for investors, operators, and policy professionals. The interaction between sales volumes, pricing strategies, and the regulatory framework, including the wholesale tax, will continue to shape the market’s trajectory. As previously reported by Hemp Gazette, creating a multifaceted commercial and regulatory environment that requires continuous analysis.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
